THURSDAY, MAY 26, 2016 / JEUDI 26 MAI 2016 | ||||||
|
||||||
09.30 11.00 |
EMERGING INFECTIOUS DISEASES – PART 2 /LES MALADIES INFECTIEUSES ÉMERGENTES – PARTIE 2
|
|||||
The "Médecins Sans Frontières" experience with Ebola / Ebola : l’expérience de Médecins Sans Frontières Armand SPRECHER, Médecins Sans Frontières, Brussels - Belgium |
||||||
Lessons learned from the Ebola epidemics / Leçons à tirer de l’épidémie d’Ebola Abdoul Habib BEAVOGUI, National Center of Formation and Rural Health Research, Maférinyah - Guinea |
||||||
How to implement research findings during a public health crisis? Comment appliquer les résultats de recherche pendant une crise de santé publique ? Jean-François DELFRAISSY, ANRS, Paris - France |
||||||
07 Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults | ||||||
Authors: Macaya DOUOGUIH, Neil GOLDSTEIN, Stephan BART, Kerstin LUHN, Wilbert VAN DUIJNHOVEN, Carla TRUYERS, Benoit CALLENDRET, on behalf of the EBL1002 study group |
||||||
Janssen Infectious Diseases and Vaccines, Leiden - The Netherlands | ||||||
09.30 11.00 |
ORAL COMMUNICATION SESSION /SESSION DE COMMUNICATIONS ORALES
|
|||||
08 Recent trends and characteristics of STI in men having sex with men in France | ||||||
Authors: Ndeindo NDEIKOUNDAM (1), Delphine VIRIOT (1), Bertille de BARBEYRAC (2), Agathe GOUBARD (3), Nicolas DUPIN (4), Michel JANIER (5), Isabelle ALCARAZ (6), Michel OHAYON (7), Nathalie SPENATTO (8), Chantal VERNAY-VAISSE (9), Florence LOT (1) |
||||||
(1) French Institute of Health Watch, Saint-Maurice - France | ||||||
(2) National reference center for chlamydiae, Bordeaux - France | ||||||
(3) National reference center for gonococcus, Paris - France | ||||||
(4) National reference center for syphilis, Paris - France | ||||||
(5) Saint-Louis Hospital, Paris - France | ||||||
(6) Dron Hospital, Tourcoing - France | ||||||
(7) Le 190, Sexual Health Center, Paris - France | ||||||
(8) Toulouse University Hospital, Toulouse - France | ||||||
(9) Bouches du Rhône Department Council, Marseille - France | ||||||
09 A new target for rapid HIV screening: erotic shows | ||||||
Authors: Mireille BONIERBALE (1), Patricia ENEL (2), Florence BRUNEL-DALMAS (3), Karine BAUMSTARCK (4) | ||||||
(1) Sainte Marguerite University Hospital, AIUS, Interdisciplinary association of sexology, CRIAVS, Marseille - France | ||||||
(2) Sainte Marguerite University Hospital, COREVIH POC, South-East Regional HIV network committee, Marseille - France | ||||||
(3) Edouard Herriot University Hospital, Infectious diseases Unit, Lyon - France | ||||||
(4) Aix-Marseille University, EA 3279 Public health research Unit: quality of life and chronic diseases, Marseille - France | ||||||
010 PLHIV over age 40: healthcare experience and comorbidities in 2015, France | ||||||
Authors: Mathilde COUDRAY, Elisabete de CARVALHO | ||||||
SIS Observatory department of SIS Reseau, Montpellier - France | ||||||
011 The R263K resistance substitution dicreases levels ofintegrated HIV DNA over time | ||||||
Authors: Thibault MESPLÈDE, Mark WAINBERG | ||||||
McGill University, Montreal - Canada | ||||||
012 Cell-associated HIV-1 multiply spliced RNA level is an independent predictor of disease progression without ART and CD4:CD8 ratio normalization on ART | ||||||
Authors: Alexander PASTERNAK, Jan PRINS, Ben BERKHOUT | ||||||
AMC, Amsterdam - The Netherlands | ||||||
013 A combination of broadly neutralizing antibodies prevents in vitro SHIV162p3 cell-free transmission more efficiently than cell to cell transmission | ||||||
Authors: K. SUPHAPHIPHAT (1), M. TOLAZZI (2), G. SCARLATTI (2), R. LEGRAND (1), M. CAVARELLI (1) | ||||||
(1) Paris-Sud University, CEA, Immunology of viral infection and auto-immune diseases (IMVA) UMER1184, IDMIT infrastructure, iMETI/DRF, Fontenay-aux-Roses - France |
||||||
(2) Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan - Italy | ||||||
014 Phenotypic, functional and kinetic parameters associated with early control of viremia in newborn macaques infected with attenuated SIV | ||||||
Authors: M. SALAS (1), C.-J. BRENNER (2), P. FROST (2), R. WHITE (1), V.-L. HODARA (1), L.-D. GIAVEDONI (1), E. DICK (2), G.-B. HUBBARD (2), M.-C. GAUDUIN (1) | ||||||
(1) Texas Biomedical Research Institute, Department of Immunology and Virology, San Antonio, Texas - USA | ||||||
(2) Southwest National Primate Research Center, Department of Primate Medicine, San Antonio, Texas - USA | ||||||
015 A new generic real-time PCR kit for hepatitis delta RNA viral load quantification | ||||||
Authors: Joany CASTERA-GUY (1), Edouard TUAILLON (2,3), Pierre-Alain RUBBO (1), Fréderic LE GAL (4), Emmanuel GORDIEN (4) | ||||||
(1) Omunis SAS, Clapiers - France | ||||||
(2) Montpellier University, UMR 1058 INSERM/EFS, “Pathogenesis and control of chronic infections”, Montpellier - France | ||||||
(3) Montpellier University Hospital, Bacteriology and Virology Department, Montpellier - France | ||||||
(4) Avicienne Hospital, Bacteriology-Virology-Hygiene Laboratory, EA3604, Paris - France | ||||||
11.30 13.00 |
MANAGING HIV INFECTION – PART 2 /GESTION DES INFECTIONS PAR LE VIH – PARTIE 2
|
|||||
New immunological tools for HIV research and monitoring |
||||||
The HIV PreP debate / Débat sur la PreP Laurent COTTE, Croix-Rousse Hospital, Lyon - France |
||||||
016 Study of the inhibition mechanism of HIV-1 integrase by Diketoacids molecules | ||||||
Authors: Léa EL KHOURY (1,2), Zeina HOBAIKA (2), Krystel EL HAGE (2,3,4), Serge FERMANDJIAN (3) , Jean-Philip PIQUEMAL (1), Nohad GRESH (1,3), Richard G. MAROUN (2) |
||||||
(1) Sorbonne University, UPMC Univ Paris 06, CNRS, Theoretical Chemistry Laboratory, Paris - France | ||||||
(2) Saint Joseph University, Faculty of Sciences, UR EGFEM, Structure and Interactions of Macromolecules Laboratory, Beirut - Lebanon | ||||||
(3) Biomedical UFR, Chemistry and Biology Nucleo(S)Tides and Immunology for Therapy (CBNIT), UMR 8601 CNRS, Paris - France | ||||||
(4) University of Basel, Department of Chemistry, Basel - Switzerland | ||||||
017 Comorbid diseases and risk factors assessment in people with HIV by systematic screening approach: results of a practice survey in a routine HIV clinic setting in the South of France | ||||||
Authors: P. PHILIBERT, G. PENARANDA, L. CHICHE, G. MBOUNGOU, P. HALFON | ||||||
European Hospital, Marseille - France | ||||||
13.15 14.00 |
INDUSTRY-SPONSORED SYMPOSIUM BY GILEAD
|
|||||
|
||||||
HCV RNA NS5B polymerase / L’ARN polyémérase NS5B du VHC |
||||||
From hepatitis C to "viral disease C" / De l’hépatite C à « la maladie virale C » |
||||||
14.00 14.30 |
MODERN ART
|
|||||
Initial success: new strategies for improving the success of first treatment |
||||||
Durable success: new strategies for maintaining long-term success |
||||||
14.30 16.00 |
THREE HOT DEBATES IN HIV INFECTION /TROIS DÉBATS BRÛLANTS SUR L’INFECTION PAR LE VIH
|
|||||
HIV PreP opens the door to STDs / PreP : porte ouverte aux MST ? | ||||||
Pros/ Pour : Alain LAFEUILLADE, Sainte Musse Hospital, Toulon - France | ||||||
Cons/ Contre : Mark WAINBERG, McGill University, Montreal - Canada | ||||||
Every day triple-drug regimens remain the gold standard in HIV / La trithérapie quotidienne demeure le traitement de référence contre le VIH | ||||||
Pros/ Pour : Stefano VELLA, National Health Institute, Rome - Italy | ||||||
Cons/ Contre : José GATELL, University of Barcelona, Barcelona - Spain | ||||||
HIV cure is unachievable / La guérison du VIH est inatteignable | ||||||
Pros/ Pour : Marie-Lise GOUGEON, Pasteur Institute, Paris - France | ||||||
Cons/ Contre : Jean-Pierre ROUTY, McGill University, Montreal - Canada | ||||||
16.30 17.30 |
JOEP LANGE KEYNOTE MEMORY LECTURE
|
|||||
Live webcast session under the auspices of ViiV Healthcare / Avec le parrainage de ViiV Healthcare | ||||||
The future of HIV care / L’avenir des soins contre le VIH Roy GULICK, Cornell University, New York - USA |
||||||
17.30 19.00 |
INDUSTRY-SPONSORED SYMPOSIUM BY MSD
|
|||||
Simplicity and durability? / Simplicité et durabilité ? |
||||||
Genetic barrier and efficacy? / Barrière génétique et efficacité ? |
||||||
Clinical trials and real world data? / Données cliniques et données de vie réelle |
||||||
FRIDAY, MAY 27, 2016 / VENDREDI 27 MAI 2016 | ||||||
|
||||||
09.30 10.30 |
MANAGING HEPATITIS VIRUSES – PART 2 /GESTION DES VIRUS DES HÉPATITES – PARTIE 2 |
|||||
|
||||||
Treatment of HCV genotype 3 patients in 2016 / Le traitement des patients atteints du VHC de génotype 3 en 2016 Marc BOURLIÈRE, Saint Joseph Hospital, Marseille - France |
||||||
Scale up for new oral hepatitis C therapies in developping countries Assurer l’accès aux nouvelles thérapies orales contre l’hépatite C dans les pays en voie de développement Victor de LEDINGHEN, Bordeaux University Hospital, Bordeaux - France |
||||||
018 Combination of non-invasive methods for the assessment of liver fibrosis in patients with chronic liver diseases: results of the ELASTIC real life study | ||||||
Authors: P. PHILIBERT, G. PENARANDA, L. CHICHE, P. SOW, G. MBOUNGOU, W. BIDAUT, D. MATHIEU, F. RETORNAZ, J. ALLEMAND, P. HALFON | ||||||
European Hospital, Marseille - France | ||||||
019 HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir | ||||||
Authors: Harel DAHARI (1,2), Laetitia CANINI (1,3), Frederik GRAW (4), Susan L. UPRICHARD (1), Evaldo S.A. ARAUJO (5), Guillaume PENARANDA (6), Emilie COQUET (6), Aurélie RISO (8), Christophe RENOU (7), Marc BOURLIÈRE (8), Scott J. COTLER (1), Philippe HALFON (6,9) |
||||||
(1) Loyola University Medical Center, Division of Hepatology, The Program for Experimental & Theoretical Modeling, Maywood, Illinois - USA | ||||||
(2) Theoretical Biology & Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico - USA | ||||||
(3) University of Edinburgh, Center for Immunity, Infection and Evolution, Edinburgh - UK | ||||||
(4) Heidelberg University, Center for Modeling and Simulation in the Biosciences, BioQuant Center, Heidelberg - Germany | ||||||
(5) University of Sao Paulo Hospital das Clinicas, Sao Paulo - Brazil | ||||||
(6) Alphabio Laboratory, Marseille - France | ||||||
(7) Hyeres Hospital, Division of Hepatology, Hyeres - France | ||||||
(8) Saint Joseph Hospital, Division of Hepatology, Marseille - France | ||||||
(9) European Hospital, Internal Medicine and Infectious Diseases, Marseille - France | ||||||
09.30 11.00 |
SESSION COREVIH TRANSVERSAL VIEWS ON PREP /REGARDS CROISÉS SUR LA PREP
|
|||||
PreP according to national recommendations / La PreP selon les recommandations nationales Isabelle POIZOT-MARTIN, AP-HM, Marseille - France |
||||||
Local experience: PreP according to the clinical doctor / L’expérience locale : la PreP selon le médecin clinicien Patrick PHILIBERT, European Hospital, Marseille - France |
||||||
PreP through the eyes of the associative companion / La PreP vue par l’accompagnant associatif Vincent CASTELAS, AIDES, Marseille - France |
||||||
The Quebec experience / L’expérience québécoise Réjean THOMAS, Clinique l’Actuel, Montreal - Canada |
||||||
10.30 11.00 |
HOT DEBATE IN HEPATITIS INFECTIONS /DÉBAT BRÛLANT SUR LES HÉPATITES
|
|||||
Anti-HCV DAA are needed whatever liver fibrosis is Les Anti-VHC à action directe sont nécessaires quel que soit le stade de fibrose hépatique |
||||||
Pros/ Pour : Albert TRAN, Nice University Hospital, Nice - France | ||||||
Cons/ Contre : Pablo BARREIRO, La Paz University Hospital, Madrid - Spain | ||||||
11.30 12.30 |
MANAGING HIV INFECTION – PART 3 / GESTION DES INFECTIONS PAR LE VIH – PARTIE 3
|
|||||
Progress toward HIV cure / Les progrès vers la guérison du VIH Daniel KURITZKES, Harvard Medical School, Boston - USA |
||||||
Prospects for a HIV vaccine / Les perspectives d’un vaccin contre le VIH Dan BAROUCH, Harvard Medical School, Boston - USA |
||||||
020 Engineering of macaque CD4+ T cells and CD34+ hematopoietic stem cells resistant to in vitro SIV Infection using zinc finger nucleases | ||||||
Authors: Peter LENTZ (1), Gregory BONELLO (1), Fuchun ZHOU (1), Mary SALAS (1), Magdalena CEPEDA (1), Robert WHITE (1), Marie-Claire GAUDUIN (1,2) | ||||||
(1) Texas Biomedical Research Institute, San Antonio, Texas - USA | ||||||
(2) The Southwest Primate Research Center, San Antonio, Texas - USA | ||||||
12.30 13.30 |
LUNCH SESSION
|
|||||
New approaches toward STDs screening and diagnosis with the new CeGIDD model of care Les nouvelles stratégies de lutte contre les IST Thierry TROUSSIER, Directorate General for Health, Paris - France |
||||||
Performance of rapid diagnostic tests for the screening of HIV infection during primary infection and at the chronic stage L’efficacité des tests rapides de diagnostic pour le dépistage du VIH pendant la primo-infection et à un stade chronique Agnès GAUTHERET-DEJEAN, Paris Descartes University, Paris - France |
||||||
The French surveillance system of syphilis: current epidemiological trends Le système français de surveillance du syphillis: les orientations épidémiologiques actuelles Nadjet BENHADDOU, Cochin Hospital, Paris - France |
||||||
Chlamydiae’s screening and prognosis / Dépistage et diagnostic des infections à chlamydiae Bertille de BARBEYRAC, University of Bordeaux, Bordeaux - France |
||||||
13.30 14.30 |
MANAGING HEPATITIS VIRUSES - PART 3 /GESTION DES VIRUS DES HÉPATITES – PARTIE 3
|
|||||
Prospects for current hepatitis C treatment failures Pistes de lutte contre les échecs thérapeutiques dans le traitement de l’hépatite C Vicente SORIANO, La Paz University Hospital, Madrid - Spain |
||||||
Search for chronic HBV infection curative therapies / Recherche de traitements curatifs contre le VHB chronique Markus CORNBERG, University of Hannover, Hannover - Germany |
||||||
14.40 16.00 |
EMERGING INFECTIOUS DISEASES - PART 3 /LES MALADIES INFECTIEUSES ÉMERGENTES – PARTIE 3
|
|||||
Multi-resistant tuberculosis / La tuberculose multi-résistante Maryline BONNET, IRD, Kampala - Uganda |
||||||
Facing the influenza challenge / Affronter le défi de la grippe Bruno LINA, INSERM, Lyon - France |
||||||
Zika virus: past, present and future / Le virus Zika : avant, maintenant et après Arnaud FONTANET, Pasteur Institute, Paris - France |
||||||
16.00 |
SYMPOSIUM CONCLUSION |
|||||